Ischemic cerebro vascular attack. cerebro vascular syndrom
Conditions
Interventions
Intervention 1: The intervention group, in addition to the current anti-ischemic drugs, ITM, based protocol will be prescribed. - Traditional Therapy package includes an oral syrup safflower extract a
Treatment - Drugs
The intervention group, in addition to the current anti-ischemic drugs, ITM, based protocol will be prescribed. - Traditional Therapy package includes an oral syrup safflower extract and safflower oil
Routin anti-ischemic drugs plus a placebo given to the control group. Current treatments include aspirin 325 mg daily, and 20 mg Trvstatyn and, if not above the patient's creatinine is 30 cc daily Pir
Sponsors
Vice chancellor for research,Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In our study, the inclusion criteria encompassed patients whom were discovered to have focal neurological symptoms after their brain imaging, being diagnosed with ischemic CVA. On the other hand, the exclusion criteria were as follows: 1. patients with focal neurological findings ith regard to the candidate symptoms of venous rTPA; 2. patients with symptoms in less than 24 hours of a TIA with normal imaging raises; 3. patients on admission with NIHSS Score and analytically based on a bad prognosis. 4. patients with chronic systemic diseases such as uremia, chronic liver disease, and high blood pressure a potential impact would be on our protocol and our intervention would accelerate HIV disease; 6. patients with possible teratogenic effects of safflower pregnancy; 7. patients having any evidence of brain hemorrhage; 8. patients receiving anticoagulant (heparin or warfarin); 9. incidence of venous infarcts in venous sinus thrombosis; 10. patients reluctant to continue double-blind treatment. During hospitalization, the patients were visited on a daily basis by experts who closely supervised the treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score of disability based on Questionnaire NIHSS. Timepoint: Baseline and one month after presentation. Method of measurement: Clinical examination by an expert on the NIHSS score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical markers. Timepoint: Baseline and one month after the initial visit. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDelshad Elahe
Mashhad University of Medical Sciences
Outcome results
None listed